PeproMene Bio announced study demonstrating strong polyfunctionality of novel chimeric antigen receptor (CAR) T cells
- Written by PR Newswire
![]() |
Polyfunctionality correlates with a patient's remission lasting over 18 months with the CAR T cell therapy
IRVINE, Calif., Aug. 7, 2024 /PRNewswire/ -- PeproMene Bio, Inc., a clinical-stage biotech company developing novel therapies for cancers and immune disorders, today announced that City of Hope-developed BAFF-R CAR T, known as...















